Home / News / Product News
New Arrival: Olmetab Plus : Better option for higher SBP and Stage-2 Hypertension
Olmetab Plus is a combination preparation of Olmesartan Medoxomil and Hydrochlorothiazide. Olmesartan Medoxomil, a prodrug, is hydrolyzed to Olmesartan during absorption from the gastrointestinal tract. Olmesartan is a selective angiotensin II receptor (AT1 subtype) antagonist. It blocks the actions of angiotensin II mediated by the AT1 receptor, regardless of the source or route of synthesis of angiotensin II.
Hydrochlorothiazide is a thiazide diuretic. Hydrochlorothiazide reduces plasma volume with consequent increase in plasma renin activity, increases aldosterone secretion & urinary Potassium loss and decreases serum Potassium. The renin-aldosterone link is mediated by angiotensin II.
So, co-administration of an angiotensin II receptor antagonist (like-Olmesartan Medoxomil) with diuretics tends to reverse the Potassium loss associated with these diuretics.
It is indicated for the treatment of hypertension. This combination preparation is indicated in patients whose blood pressure is not adequately controlled on Olmesartan alone. It is not indicated for initial therapy.
Olmetab Plus is available as 20/12.5 mg and 40/12.5 mg tablet in alu-alu blister strip.